

Appointment of healthcare industry and venture capital veteran

Dr Geoff Brooke as Chairman

- Appointment of healthcare industry and venture capital veteran, Dr Geoff Brooke, as new Chairman.
- Adds significant life sciences and financial expertise to the Actinogen Board, with Dr Brooke having 30 years' international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies.
- Dr Brooke was Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures and is a Non-Executive Director of ASX-listed company, Acrux Limited (ASX:ACR).
- Dr Brooke's experience will be invaluable as Actinogen begins patient recruitment in their XanADu Phase II Alzheimer's trial in early Q2 2017 and progresses through to study completion and data read-out in early 2019.

Sydney, 1 March 2017: Actinogen Medical (ASX: ACW) is pleased to announce that it has appointed healthcare industry and venture capital veteran, Dr Geoff Brooke, as Chairman, effective 1st March.

The appointment adds significant life science and financial expertise to the Actinogen Board, with Dr Brooke having 30 years' international experience as the founder, lead investor and/or Chairman/Director of numerous healthcare companies with a realised value of more than \$1.5 billion.

Most notably, he was the Managing Director and Founder of leading life sciences venture capital firm, GBS Ventures - one of Asia Pacific's premier investors in the healthcare space. There, Dr Brooke was responsible for GBS's healthcare venture activity in the region and raised \$450 million in venture and private equity funds, focused on biopharmaceuticals, medical devices and services. He was also responsible for numerous investments and exits via NASDAQ and ASX public listings and trade sales, as well as being lead investor in numerous investments syndicated in multiple rounds with premier US venture firms.

Dr Brooke was also President and Founder of US-based seed healthcare venture capital firm, Medvest Inc, with investors including the venture capital arm of leading global multinational medical devices, pharmaceutical and consumer packaged goods manufacturer, Johnson & Johnson. Medvest was focused on founding companies based upon health care-related technology, including pharmaceuticals, biotechnology, therapeutic devices, medical services and information systems.

Dr Brooke now acts a private investor in, and independent director for, a number of small to medium-sized Australian and US private and public companies, including Non-Executive Director for ASX-listed company, Acrux Limited (ASX:ACR).

He holds a Bachelor of Medicine and a Bachelor of Surgery from Melbourne University and a Masters of Business Administration from IMEDE Switzerland (now IMD).

"We are thrilled to have someone of Geoff's calibre joining Actinogen as Chairman. Geoff brings a wealth of expertise across the Australian and US listed healthcare space and in-depth knowledge of all aspects of financing healthcare and life sciences companies," said Dr Bill Ketelbey, CEO of Actinogen Medical.

“His knowledge will be invaluable as we progress through to study completion and data read-out of our XanADu Phase II clinical trial - the largest global Alzheimer’s dementia study conducted by an Australian biotech company – which is on target to treat first patients with Xanamem™ in early Q2 2017.”

As part of his appointment and subject to shareholder approval (if required), Dr Brooke will be granted 5 million options exercisable at \$0.10 and expiring eight years from grant. The options will vest in three tranches, subject to continuous service up to the applicable vesting date, as follows:

- 2 million - one year from grant;
- 1.5 million - two years from grant; and
- 1.5 million - three years from grant.

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen Medical's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer’s disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer’s disease.

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer’s disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer’s disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. Xanamem™’s novel mechanism of action sets it apart from other Alzheimer’s treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.

ACTINOGEN MEDICAL LIMITED TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW

Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 8964 7401

WEB www.actinogen.com.au